Novel Drug Delivery Systems (NDDS) Market Size

New Drug Delivery Systems (NDDS) Market Analysis

The Novel Drug Delivery Systems (NDDS) Market is expected to grow from USD 269.10 billion in 2023 to USD 350.97 billion in 2028, registering a CAGR of 5.46% during the forecast period.

The emergence of the COVID-19 pandemic significantly impacted the novel drug delivery systems market due to supply chain disruptions and delayed clinical trials for new drug delivery systems due to restrictions on non-essential research activities, site closures, and challenges in patient recruitment. Additionally, the pharmaceutical and biotech industry's resources were redirected toward COVID-19 vaccine development and related research, which diverted attention and resources away from developing novel drug delivery systems for other therapeutic areas and impacted the growth of the NDDS market. For instance, during the initial phase of the COVID-19 pandemic, AstraZeneca received more than USD 1,000 million in funding from the United States Health Department's Biomedical Advanced Research and Development Authority (BARDA) for the development, production, and delivery of the University of Oxford's COVID-19 vaccine. However, many studies referred to different novel delivery systems, and positive outcomes from these studies significantly raised the market growth in the later phase of the pandemic. For instance, according to a research study published in the Biomedicine and Pharmacotherapy Journal in November 2021, nanoparticles were very useful in the drug delivery process for treating COVID-19. The study demonstrated that nanoparticles as delivery vehicles could improve drug delivery's effectiveness. Hence, the availability of such research fuelled the market growth in the later phase of the pandemic. This was expected to have a long-term impact of COVID-19 on the novel drug delivery systems (NDSS) market. The market is predicted to continue its growth trend over the forecast period.

The growth of the global novel drug delivery systems market is primarily driven by the rising need for a controlled drug delivery system owing to the increasing burden of chronic diseases such as diabetes, cardiovascular, renal disease, asthma, cancer, and others. With the increasing awareness about these diseases, the demand for effective and advanced therapeutics is increasing, which is expected to drive the companies to develop novel drug delivery systems and fuel the market's growth.

According to a research study published in the Journal of the Formosan Medical Association in October 2021, when a group of people aged 40 years to 74 years was studied, the overall prevalence rate of carotid plaque and diabetes mellitus (DM) was found to be 34.4% and 10.7%, respectively, while the age-specific prevalence rates of DM and carotid plaque were nearly linearly correlated in both genders among the studied population. This data shows a significant burden of several chronic diseases worldwide. Similarly, the Global Cancer Observatory Data updated in March 2021 showed that the global burden of cancer is expected to increase to 28.9 million by 2040 from 19.3 million in the most recent year data available. Hence, the high and increasing burden of chronic diseases is expected to lead the way for developing novel drug delivery systems with the new investments and advancements in the area and boost the studied market growth over the forecast period.

Moreover, the technological advancements in the drug delivery systems and new investment by the private as well as government entities, coupled with the new product launches, collaboration, and mergers and acquisitions by the key companies in the market, are further expected to boost growth in the novel drug delivery systems market. For instance, in June 2022, Gufic Biosciences Ltd. launched a novel Dual Chamber Bags (DCB) drug delivery system. These Dual Chamber Bags are 2-chamber IV bags made up of polypropylene (DEHP free) with a peelable aluminum foil, allowing the storage of unstable drugs that need reconstitution just before the administration to the patient. Therefore, owing to the abovementioned factors, the novel drug delivery systems market is expected to grow during the forecast period. However, stringent regulatory guidelines, product recalls, and stability issues are expected to restrain the growth of the studied market over the forecast period.